EMA Recommends Granting a Marketing Authorisation for Tarlatamab By Ogkologos - April 17, 2026 5 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the treatment of adult patients with extensive-stage SCLC Source RELATED ARTICLESMORE FROM AUTHOR Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up MOST POPULAR Avasopasem Shields Normal Cells from Radiation, Helps Kill Cancer Cells June 23, 2021 EMA Recommends Extending Indications for Pembrolizumab to Include Adjuvant Treatment in... October 6, 2023 Cancer in My Community: Caring for the Whole Patient in Brazil December 7, 2023 Biomarker Analyses in Patients with HER2-positive or HER2-low Gastric and Gastro-oesophageal... May 21, 2024 Load more HOT NEWS Study Estimates That 22% Of Breast Cancers Are Overdiagnosed And Won’t... EMA Recommends Extension of Indications for Sugemalimab FDA Approves Second CAR T-Cell Therapy for Lymphoma Vaping Pods Produce High Nicotine Levels in Young Users
